S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14

Compare Stocks

Enter up to ten stock symbols separated by a comma or space (ex. SGEN,NVZMY,TECH,ARGX,BIIB).

Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
SGEN
Seagen
$143.00
-2.4%
$139.18
$105.43
$192.79
$26.32B0.851.13 million shs1.10 million shs
NVZMY
Novozymes A/S
$60.90
-3.1%
$65.77
$57.85
$83.31
$13.90B0.5718,841 shs20,436 shs
TECH
Bio-Techne
$359.09
-3.2%
$407.05
$335.02
$543.85
$14.09B1.24267,344 shs241,552 shs
ARGX
argenx
$304.71
-3.5%
$307.95
$249.50
$356.78
$16.34B1.11272,656 shs255,495 shs
BIIB
Biogen
$195.71
-3.5%
$207.02
$187.16
$468.55
$28.66B0.421.29 million shs1.20 million shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
SGEN
Seagen
-2.42%+19.72%-0.96%+15.17%-3.53%
NVZMY
Novozymes A/S
-3.09%+0.15%-9.19%+0.73%-16.92%
TECH
Bio-Techne
-3.22%+6.03%-12.85%-9.82%-10.23%
ARGX
argenx
-3.55%+7.16%-3.86%+5.84%+10.51%
BIIB
Biogen
-3.54%+2.43%-7.92%-7.07%-30.35%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionCommunity RankDividend StrengthCompany OwnershipEarnings & Valuation
SGEN
Seagen
2.31 of 5 Stars
2.44.40.04.20.6
NVZMY
Novozymes A/S
1.86 of 5 Stars
3.13.31.70.01.3
TECH
Bio-Techne
2.89 of 5 Stars
3.34.31.73.31.9
ARGX
argenx
1.70 of 5 Stars
2.54.50.00.80.6
BIIB
Biogen
2.29 of 5 Stars
4.34.90.01.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
SGEN
Seagen
2.70
Buy$160.0011.89% Upside
NVZMY
Novozymes A/S
2.13
Hold$425.00597.87% Upside
TECH
Bio-Techne
2.60
Buy$504.1740.40% Upside
ARGX
argenx
3.00
Buy$360.9418.45% Upside
BIIB
Biogen
2.50
Buy$275.4740.75% Upside

Current Analyst Ratings

Latest SGEN, NVZMY, TECH, ARGX, and BIIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2022
ARGX
argenx
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
5/6/2022
ARGX
argenx
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight€350.00 ➝ €370.00
5/5/2022
TECH
Bio-Techne
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$520.00 ➝ $500.00
5/5/2022
TECH
Bio-Techne
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$600.00 ➝ $500.00
5/4/2022
BIIB
Biogen
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$240.00 ➝ $225.00
5/4/2022
BIIB
Biogen
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$219.00 ➝ $210.00
5/3/2022
ARGX
argenx
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$375.00
4/29/2022
NVZMY
Novozymes A/S
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeReduce ➝ Hold
4/28/2022
BIIB
Biogen
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
4/27/2022
NVZMY
Novozymes A/S
Nordea Equity Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Hold
4/25/2022
TECH
Bio-Techne
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeEqual Weight ➝ Underweight$400.00 ➝ $370.00
(Data available from 5/19/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
SGEN
Seagen
$1.57B16.72N/AN/A$16.76 per share8.53
NVZMY
Novozymes A/S
$2.38B5.84$2.22 per share27.44$8.51 per share7.16
TECH
Bio-Techne
$931.03M15.13$8.02 per share44.76$40.40 per share8.89
ARGX
argenx
$539.42M30.29N/AN/A$49.05 per share6.21
BIIB
Biogen
$10.98B2.61$26.70 per share7.33$74.61 per share2.62

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
SGEN
Seagen
-$674.47M-$3.77N/AN/AN/A-41.32%-21.86%-18.07%8/4/2022 (Estimated)
NVZMY
Novozymes A/S
$500.53M$1.7435.0033.107.9621.04%27.43%13.88%N/A
TECH
Bio-Techne
$140.41M$5.4865.5343.112.0120.95%16.82%12.21%8/4/2022 (Estimated)
ARGX
argenx
-$408.27M-$11.54N/AN/AN/A-147.47%-32.54%-29.44%8/4/2022 (Estimated)
BIIB
Biogen
$1.56B$9.7720.0311.901.2413.40%23.46%10.85%7/28/2022 (Estimated)

Latest SGEN, NVZMY, TECH, ARGX, and BIIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/20223/31/2022
ARGX
argenx
-$5.08-$4.36+$0.72N/AN/AN/A  
5/4/2022Q3 2022
TECH
Bio-Techne
$1.75$1.96+$0.21$2.44$279.27 million$290.40 million    
5/3/2022Q1 2022
BIIB
Biogen
$4.41$3.62-$0.79$5.18$2.50 billion$2.53 billion    
4/28/2022Q1 2022
SGEN
Seagen
-$0.98-$0.74+$0.24-$0.74$401.75 million$426.50 million      
3/3/2022Q4 2021
ARGX
argenx
-$4.88-$4.76+$0.12-$4.76$18.87 million$44.84 million
(Earnings results data provided by Zacks Investment Research)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
SGEN
Seagen
N/AN/AN/AN/AN/A
NVZMY
Novozymes A/S
$0.550.90%N/A31.61%N/A
TECH
Bio-Techne
$1.280.36%N/A23.36%N/A
ARGX
argenx
N/AN/AN/AN/AN/A
BIIB
Biogen
N/AN/AN/AN/AN/A

Latest SGEN, NVZMY, TECH, ARGX, and BIIB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2022
TECH
Bio-Techne
quarterly$0.320.3%5/13/20225/16/20225/27/2022
3/15/2022
NVZMY
Novozymes A/S
$0.5670080.95%3/17/20223/18/20224/5/2022
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
SGEN
Seagen
N/A
5.22
4.70
NVZMY
Novozymes A/S
0.30
1.38
0.85
TECH
Bio-Techne
0.14
3.56
2.79
ARGX
argenx
N/A
8.44
8.08
BIIB
Biogen
0.56
2.01
1.70

Ownership

Institutional Ownership

CompanyInstitutional Ownership
SGEN
Seagen
90.37%
NVZMY
Novozymes A/S
0.03%
TECH
Bio-Techne
94.36%
ARGX
argenx
58.76%
BIIB
Biogen
83.92%

Insider Ownership

CompanyInsider Ownership
SGEN
Seagen
27.3%
NVZMY
Novozymes A/S
N/A
TECH
Bio-Techne
4.1%
ARGX
argenx
N/A
BIIB
Biogen
0.62%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
SGEN
Seagen
2,675184.08 million133.82 millionOptionable
NVZMY
Novozymes A/S
6,527228.26 millionN/ANot Optionable
TECH
Bio-Techne
2,60039.23 million37.63 millionOptionable
ARGX
argenx
65053.62 millionN/AOptionable
BIIB
Biogen
9,610146.45 million145.54 millionOptionable

SGEN, NVZMY, TECH, ARGX, and BIIB Headlines

SourceHeadline
Biogens Alex Cameron Discusses Biogen-MIT Biotech in Action - CSRwire.comBiogen's Alex Cameron Discusses Biogen-MIT Biotech in Action - CSRwire.com
csrwire.com - May 16 at 2:39 PM
Biogens Aduhelm cant catch a break even in Alzheimers trials as neurologists worry about safety, efficacy - FiercePharmaBiogen's Aduhelm can't catch a break even in Alzheimer's trials as neurologists worry about safety, efficacy - FiercePharma
fiercepharma.com - May 16 at 2:39 PM
How Many Biogen Inc. (NASDAQ:BIIB) Shares Do Institutions Own?How Many Biogen Inc. (NASDAQ:BIIB) Shares Do Institutions Own?
finance.yahoo.com - May 16 at 2:39 PM
Multiple Sclerosis Treatment Market Size And Forecast | Teva Pharmaceutical Industries, Bayer, Biogen Idec, Pfizer, Novartis – Queen Anne and Mangolia News - Queen Anne and Mangolia NewsMultiple Sclerosis Treatment Market Size And Forecast | Teva Pharmaceutical Industries, Bayer, Biogen Idec, Pfizer, Novartis – Queen Anne and Mangolia News - Queen Anne and Mangolia News
magnolianews.net - May 14 at 11:54 PM
Biogen All but Throws in the Towel on Once-Promising Alzheimers DrugBiogen All but Throws in the Towel on Once-Promising Alzheimer's Drug
gurufocus.com - May 12 at 5:09 PM
Scribe Pursues CRISPR Therapies with Expanded Biogen Collaboration - Genetic Engineering & Biotechnology NewsScribe Pursues CRISPR Therapies with Expanded Biogen Collaboration - Genetic Engineering & Biotechnology News
genengnews.com - May 12 at 3:50 PM
Chancery Orders Biogen To Give Documents To Investor - Law360Chancery Orders Biogen To Give Documents To Investor - Law360
law360.com - May 11 at 6:32 PM
Eisai, Biogen Take Another Step Toward Potential Approval of Alzheimers Drug Lecanemab - BioSpaceEisai, Biogen Take Another Step Toward Potential Approval of Alzheimer's Drug Lecanemab - BioSpace
biospace.com - May 11 at 1:32 PM
EIT Health and Biogen announce winners of first neurotechprize - PMLiVEEIT Health and Biogen announce winners of first 'neurotechprize' - PMLiVE
pmlive.com - May 11 at 8:31 AM
Biogen pivots to second amyloid-targeted Alzheimers drug with accelerated approval filing from partner Eisai - Endpoints NewsBiogen pivots to second amyloid-targeted Alzheimer's drug with accelerated approval filing from partner Eisai - Endpoints News
endpts.com - May 10 at 8:39 PM
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimers - BenzingaThe Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's - Benzinga
benzinga.com - May 10 at 10:37 AM
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimers DrugEisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
finance.yahoo.com - May 10 at 10:37 AM
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMERS DISEASE UNDER THE ACCELERATED APPROVAL PATHWAYEISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
finance.yahoo.com - May 10 at 12:06 AM
Chancery Should Order Biogen To Give Up Docs, Report Says - Law360Chancery Should Order Biogen To Give Up Docs, Report Says - Law360
law360.com - May 9 at 7:05 PM
ICYMI: Biogen CEO Michel Vounatsos to Step Down After the U.S. Governments Medicare ... - Latest Tweet by - LatestLYICYMI: Biogen CEO Michel Vounatsos to Step Down After the U.S. Government's Medicare ... - Latest Tweet by - LatestLY
latestly.com - May 9 at 8:56 AM
Biogens shakeup from the top; How to build a biotech today; David Sabatini backs out of NYU; and more - Endpoints NewsBiogen's shakeup from the top; How to build a biotech today; David Sabatini backs out of NYU; and more - Endpoints News
endpts.com - May 7 at 10:22 AM
Q3 2022 EPS Estimates for Biogen Inc. Boosted by Analyst (NASDAQ:BIIB)Q3 2022 EPS Estimates for Biogen Inc. Boosted by Analyst (NASDAQ:BIIB)
americanbankingnews.com - May 7 at 2:58 AM
SVB Leerink Analysts Lower Earnings Estimates for Biogen Inc. (NASDAQ:BIIB)SVB Leerink Analysts Lower Earnings Estimates for Biogen Inc. (NASDAQ:BIIB)
americanbankingnews.com - May 7 at 1:54 AM
Biogen Inc. (NASDAQ:BIIB) to Post Q2 2022 Earnings of $3.86 Per Share, Wedbush ForecastsBiogen Inc. (NASDAQ:BIIB) to Post Q2 2022 Earnings of $3.86 Per Share, Wedbush Forecasts
americanbankingnews.com - May 7 at 1:54 AM
Q2 2022 Earnings Forecast for Biogen Inc. (NASDAQ:BIIB) Issued By William BlairQ2 2022 Earnings Forecast for Biogen Inc. (NASDAQ:BIIB) Issued By William Blair
americanbankingnews.com - May 7 at 1:54 AM
TAR DNA Binding Protein 43 Market Size & Revenue Analysis | Biogen Inc, ImStar Therapeutics Inc., Primary Peptides – Queen Anne and Mangolia News - Queen Anne and Mangolia NewsTAR DNA Binding Protein 43 Market Size & Revenue Analysis | Biogen Inc, ImStar Therapeutics Inc., Primary Peptides – Queen Anne and Mangolia News - Queen Anne and Mangolia News
magnolianews.net - May 6 at 11:40 PM
Biogen Licensing Deal is Sweet Music for Bolstering MS Portfolio - BioSpaceBiogen Licensing Deal is Sweet Music for Bolstering MS Portfolio - BioSpace
biospace.com - May 6 at 6:40 PM
Beset by challenges with its Alzheimer’s disease drug, Biogen pivotsBeset by challenges with its Alzheimer’s disease drug, Biogen pivots
marketwatch.com - May 6 at 1:39 PM
StockWatch: Investors Unfazed by Biogen CEO Search, Aduhelm CutbacksStockWatch: Investors Unfazed by Biogen CEO Search, Aduhelm Cutbacks
genengnews.com - May 6 at 1:39 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.